Created in 2016
About Siolta Therapeutics:
Siolta Therapeutics is a clinical-stage biotech on a mission to develop next-generation microbial therapeutics aimed at the prevention and treatment of inflammatory diseases. Siolta blends expertise from microbiology, immunology, and bioinformatics to develop rationally designed microbial consortia and companion diagnostics to provide targeted live biotherapeutic products (LBPs). Since its inception in 2016, Siolta has successfully translated its preclinical POC studies into an innovative “first in human” clinical study (Phase 1b), established CGMP manufacturing, and secured $10M in funding (Khosla Ventures, Marc Benioff, and Seventure Partners).
Siolta Therapeutics leverages knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop next generation human microbiome therapeutics for the prevention and treatment of inflammatory diseases. The company is currently focused on the clinical development of its lead product for the prevention and treatment of allergic asthma. This multifaceted platform utilizes an ecosystems approach to rationally design microbial consortia and develop companion diagnostics for patient stratification. Siolta’s holistic, microbiome-based strategy represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.